{ "responseHeader":{ "status":0, "QTime":0, "params":{ "q":"iati_identifier:XM-DAC-301-2-110336-001", "fl":"*", "format":"json" } }, "response":{ "numFound":1, "start":0, "numFoundExact":true, "docs":[{ "last-updated-datetime":"2026-02-13T18:59:49Z", "last_updated_datetime":"Fri Feb 13 18:59:49 UTC 2026", "last_updated_datetime_f":"2026-02-13T18:59:49Z", "lang":"en", "default_lang":"en", "iati-identifier":"XM-DAC-301-2-110336-001", "iati_identifier":"XM-DAC-301-2-110336-001", "reporting-org.type":"15", "reporting_org_type_code":"15", "reporting-org.ref":"XM-DAC-301-2", "reporting_org_ref":"XM-DAC-301-2", "reporting-org.narrative":["International Development Research Centre","Centre de recherches pour le développement international","Centro Internacional de Investigaciones para el Desarrollo"], "reporting_org_narrative":["International Development Research Centre","Centre de recherches pour le développement international","Centro Internacional de Investigaciones para el Desarrollo"], "reporting-org.narrative.lang":["en","fr","es"], "title.narrative":["Novel nanoparticle therapeutics as alternatives to antibiotics to control Escherichia coli bacterial infection in ruminants in Ethiopia","Nouvelles nanoparticules thérapeutiques comme alternatives aux antibiotiques pour contrôler l’infection bactérienne à E coli chez les ruminants en Éth"], "title_narrative":["Novel nanoparticle therapeutics as alternatives to antibiotics to control Escherichia coli bacterial infection in ruminants in Ethiopia","Nouvelles nanoparticules thérapeutiques comme alternatives aux antibiotiques pour contrôler l’infection bactérienne à E coli chez les ruminants en Éth"], "title_narrative_text":["Novel nanoparticle therapeutics as alternatives to antibiotics to control Escherichia coli bacterial infection in ruminants in Ethiopia","Nouvelles nanoparticules thérapeutiques comme alternatives aux antibiotiques pour contrôler l’infection bactérienne à E coli chez les ruminants en Éth"], "title.narrative.lang":["en","fr"], "title_narrative_lang":["en","fr"], "description.type":["1"], "description_type":["1"], "description.narrative":["The dairy productivity of Ethiopian cattle is largely affected by neonatal mortality caused by infectious diseases. Bovine colibacillosis caused by enterotoxigenic Escherichia coli (E coli) is mainly responsible for diarrhea in calves. Currently, antimicrobials are the main line of treatment for bovine colibacillosis. The emergence of multidrug-resistant E coli strains, responsible for high mortality and morbidity, demonstrates an urgent need for the development of alternative antimicrobials. \n\nThe central hypothesis of this research project is that small molecule inhibitors and antimicrobial peptides targeting the outer membrane proteins of E coli can be developed into safe and effective therapies for multidrug-resistant infections. The main objective is to develop an innovative delivery system and evaluate its efficacy, safety and applicability against bovine colibacillosis. The study outcomes can lead to a more effective means for managing calf diarrhea in Ethiopia, which will promote sustainable animal agriculture, improve food security and reduce reliance on antibiotics. These findings will have broader implications for mitigating antimicrobial resistance in other low- and middle-income countries.  \n\nThis project is part of the InnoVet-AMR 2.0 program, a four-year partnership between IDRC and the United Kingdom’s Department of Health and Social Care. The initiative is aimed at reducing the emerging risk that antimicrobial resistance in animals poses to global health and food security.","La productivité laitière du bétail éthiopien est largement touchée par la mortalité néonatale causée par les maladies infectieuses. La colibacillose bovine causée par Escherichia coli entérotoxique (E coli) est principalement responsable de la diarrhée chez les veaux. Actuellement, les antimicrobiens constituent la principale ligne de traitement de la colibacillose bovine. L’émergence de souches d’E. coli multirésistantes, responsables d’une mortalité et d’une morbidité élevées, montre qu’il est urgent de développer des antimicrobiens alternatifs. \n\nL’hypothèse centrale de ce projet de recherche est que les petites molécules inhibitrices et les peptides antimicrobiens ciblant les protéines de la membrane externe d’E. coli peuvent être développés en thérapies sûres et efficaces pour les infections multirésistantes. L’objectif principal est de développer un système d’administration innovant et d’évaluer son efficacité, sa sécurité et son applicabilité contre la colibacillose bovine. Les résultats de l’étude peuvent déboucher sur un moyen plus efficace de gérer la diarrhée du veau en Éthiopie, ce qui favorisera une agriculture animale durable, améliorera la sécurité alimentaire et réduira la dépendance à l’égard des antibiotiques. Ces résultats auront des répercussions plus larges pour atténuer la résistance aux antimicrobiens dans d’autres pays à revenu faible ou intermédiaire.  \n\nCe projet fait partie du programme Solutions vétérinaires innovatrices pour la résistance aux antimicrobiens 2.0 (InnoVet-AMR 2.0), un partenariat de quatre ans entre le CRDI et le Department of Health and Social Care du Royaume-Uni. L’initiative vise à réduire les risques émergents que pose la résistance aux antimicrobiens chez les animaux pour la santé mondiale et la sécurité alimentaire."], "description_narrative":["The dairy productivity of Ethiopian cattle is largely affected by neonatal mortality caused by infectious diseases. Bovine colibacillosis caused by enterotoxigenic Escherichia coli (E coli) is mainly responsible for diarrhea in calves. Currently, antimicrobials are the main line of treatment for bovine colibacillosis. The emergence of multidrug-resistant E coli strains, responsible for high mortality and morbidity, demonstrates an urgent need for the development of alternative antimicrobials. \n\nThe central hypothesis of this research project is that small molecule inhibitors and antimicrobial peptides targeting the outer membrane proteins of E coli can be developed into safe and effective therapies for multidrug-resistant infections. The main objective is to develop an innovative delivery system and evaluate its efficacy, safety and applicability against bovine colibacillosis. The study outcomes can lead to a more effective means for managing calf diarrhea in Ethiopia, which will promote sustainable animal agriculture, improve food security and reduce reliance on antibiotics. These findings will have broader implications for mitigating antimicrobial resistance in other low- and middle-income countries.  \n\nThis project is part of the InnoVet-AMR 2.0 program, a four-year partnership between IDRC and the United Kingdom’s Department of Health and Social Care. The initiative is aimed at reducing the emerging risk that antimicrobial resistance in animals poses to global health and food security.","La productivité laitière du bétail éthiopien est largement touchée par la mortalité néonatale causée par les maladies infectieuses. La colibacillose bovine causée par Escherichia coli entérotoxique (E coli) est principalement responsable de la diarrhée chez les veaux. Actuellement, les antimicrobiens constituent la principale ligne de traitement de la colibacillose bovine. L’émergence de souches d’E. coli multirésistantes, responsables d’une mortalité et d’une morbidité élevées, montre qu’il est urgent de développer des antimicrobiens alternatifs. \n\nL’hypothèse centrale de ce projet de recherche est que les petites molécules inhibitrices et les peptides antimicrobiens ciblant les protéines de la membrane externe d’E. coli peuvent être développés en thérapies sûres et efficaces pour les infections multirésistantes. L’objectif principal est de développer un système d’administration innovant et d’évaluer son efficacité, sa sécurité et son applicabilité contre la colibacillose bovine. Les résultats de l’étude peuvent déboucher sur un moyen plus efficace de gérer la diarrhée du veau en Éthiopie, ce qui favorisera une agriculture animale durable, améliorera la sécurité alimentaire et réduira la dépendance à l’égard des antibiotiques. Ces résultats auront des répercussions plus larges pour atténuer la résistance aux antimicrobiens dans d’autres pays à revenu faible ou intermédiaire.  \n\nCe projet fait partie du programme Solutions vétérinaires innovatrices pour la résistance aux antimicrobiens 2.0 (InnoVet-AMR 2.0), un partenariat de quatre ans entre le CRDI et le Department of Health and Social Care du Royaume-Uni. L’initiative vise à réduire les risques émergents que pose la résistance aux antimicrobiens chez les animaux pour la santé mondiale et la sécurité alimentaire."], "description_narrative_text":["The dairy productivity of Ethiopian cattle is largely affected by neonatal mortality caused by infectious diseases. Bovine colibacillosis caused by enterotoxigenic Escherichia coli (E coli) is mainly responsible for diarrhea in calves. Currently, antimicrobials are the main line of treatment for bovine colibacillosis. The emergence of multidrug-resistant E coli strains, responsible for high mortality and morbidity, demonstrates an urgent need for the development of alternative antimicrobials. \n\nThe central hypothesis of this research project is that small molecule inhibitors and antimicrobial peptides targeting the outer membrane proteins of E coli can be developed into safe and effective therapies for multidrug-resistant infections. The main objective is to develop an innovative delivery system and evaluate its efficacy, safety and applicability against bovine colibacillosis. The study outcomes can lead to a more effective means for managing calf diarrhea in Ethiopia, which will promote sustainable animal agriculture, improve food security and reduce reliance on antibiotics. These findings will have broader implications for mitigating antimicrobial resistance in other low- and middle-income countries.  \n\nThis project is part of the InnoVet-AMR 2.0 program, a four-year partnership between IDRC and the United Kingdom’s Department of Health and Social Care. The initiative is aimed at reducing the emerging risk that antimicrobial resistance in animals poses to global health and food security.","La productivité laitière du bétail éthiopien est largement touchée par la mortalité néonatale causée par les maladies infectieuses. La colibacillose bovine causée par Escherichia coli entérotoxique (E coli) est principalement responsable de la diarrhée chez les veaux. Actuellement, les antimicrobiens constituent la principale ligne de traitement de la colibacillose bovine. L’émergence de souches d’E. coli multirésistantes, responsables d’une mortalité et d’une morbidité élevées, montre qu’il est urgent de développer des antimicrobiens alternatifs. \n\nL’hypothèse centrale de ce projet de recherche est que les petites molécules inhibitrices et les peptides antimicrobiens ciblant les protéines de la membrane externe d’E. coli peuvent être développés en thérapies sûres et efficaces pour les infections multirésistantes. L’objectif principal est de développer un système d’administration innovant et d’évaluer son efficacité, sa sécurité et son applicabilité contre la colibacillose bovine. Les résultats de l’étude peuvent déboucher sur un moyen plus efficace de gérer la diarrhée du veau en Éthiopie, ce qui favorisera une agriculture animale durable, améliorera la sécurité alimentaire et réduira la dépendance à l’égard des antibiotiques. Ces résultats auront des répercussions plus larges pour atténuer la résistance aux antimicrobiens dans d’autres pays à revenu faible ou intermédiaire.  \n\nCe projet fait partie du programme Solutions vétérinaires innovatrices pour la résistance aux antimicrobiens 2.0 (InnoVet-AMR 2.0), un partenariat de quatre ans entre le CRDI et le Department of Health and Social Care du Royaume-Uni. L’initiative vise à réduire les risques émergents que pose la résistance aux antimicrobiens chez les animaux pour la santé mondiale et la sécurité alimentaire."], "description.narrative.lang":["en","fr"], "description_narrative_lang":["en","fr"], "participating-org.role":["4","1","1","2","3"], "participating_org_role":["4","1","1","2","3"], "participating-org.type":["80","10","10","80","15"], "participating_org_type":["80","10","10","80","15"], "participating-org.narrative":["The Board of Trustees of the University of Illinois","United Kingdom. Department of Health and Social Care","Canada. Parliament","Canada. Parlement","Canadá. Parlamento","The Board of Trustees of the University of Illinois","International Development Research Centre","Centre de recherches pour le développement international"], "participating_org_narrative":["The Board of Trustees of the University of Illinois","United Kingdom. Department of Health and Social Care","Canada. Parliament","Canada. Parlement","Canadá. Parlamento","The Board of Trustees of the University of Illinois","International Development Research Centre","Centre de recherches pour le développement international"], "participating_org_narrative_text":["The Board of Trustees of the University of Illinois","United Kingdom. Department of Health and Social Care","Canada. Parliament","Canada. Parlement","Canadá. Parlamento","The Board of Trustees of the University of Illinois","International Development Research Centre","Centre de recherches pour le développement international"], "participating-org.narrative.lang":["en","en","en","fr","es","en","en","fr"], "participating_org_narrative_lang":["en","en","en","fr","es","en","en","fr"], "participating-org.ref":["GB-GOV-10","XM-DAC-301-2","XM-DAC-301-2"], "participating_org_ref":["GB-GOV-10","XM-DAC-301-2","XM-DAC-301-2"], "participating-org.activity-id":["GB-GOV-10-GAMRIF-WP3-Inno-Vet-AMR"], "activity-status.code":"2", "activity_status_code":"2", "activity-date.iso-date":["2024-06-20T00:00:00Z","2027-01-20T00:00:00Z"], "activity_date_iso_date":["2024-06-20T00:00:00Z","2027-01-20T00:00:00Z"], "activity-date.type":["2","3"], "activity_date_type":["2","3"], "contact-info.type":["1"], "contact_info_type":["1"], "contact-info.organisation.narrative":["International Development Research Centre","Centre de recherches pour le développement international"], "contact_info_organisation_narrative":["International Development Research Centre","Centre de recherches pour le développement international"], "contact_info_organisation_narrative_text":["International Development Research Centre","Centre de recherches pour le développement international"], "contact-info.organisation.narrative.lang":["en","fr"], "contact_info_organisation_narrative_lang":["en","fr"], "contact-info.telephone":["(+1) 613-236-6163"], "contact_info_telephone":["(+1) 613-236-6163"], "contact-info.email":["info@idrc.ca"], "contact_info_email":["info@idrc.ca"], "contact-info.website":["http://www.idrc.ca"], "contact_info_website":["http://www.idrc.ca"], "contact-info.mailing-address.narrative":["PO Box 8500, Ottawa ON Canada, K1G 3H9","CP 8500, Ottawa ON Canada, K1G 3H9"], "contact_info_mailing_address_narrative":["PO Box 8500, Ottawa ON Canada, K1G 3H9","CP 8500, Ottawa ON Canada, K1G 3H9"], "contact_info_mailing_address_narrative_text":["PO Box 8500, Ottawa ON Canada, K1G 3H9","CP 8500, Ottawa ON Canada, K1G 3H9"], "contact-info.mailing-address.narrative.lang":["en","fr"], "contact_info_mailing_address_narrative_lang":["en","fr"], "activity-scope.code":"4", "activity_scope_code":"4", "recipient-country.code":["ET"], "recipient_country_code":["ET"], "recipient-country.percentage":[100.0], "recipient_country_percentage":[100.0], "sector.vocabulary":["1"], "sector_vocabulary":["1"], "sector.code":["31182"], "sector_code":["31182"], "sector.percentage":[100.0], "sector_percentage":[100.0], "policy-marker.vocabulary":["1","1","1","1","1","1","1","1","1"], "policy_marker_vocabulary":["1","1","1","1","1","1","1","1","1"], "policy-marker.code":["1","2","3","4","5","6","7","8","9"], "policy_marker_code":["1","2","3","4","5","6","7","8","9"], "policy-marker.significance":["0","0","0","0","0","0","0","0","0"], "policy_marker_significance":["0","0","0","0","0","0","0","0","0"], "collaboration-type.code":"1", "collaboration_type_code":"1", "default-flow-type.code":"10", "default_flow_type_code":"10", "default-finance-type.code":"110", "default_finance_type_code":"110", "default-aid-type.code":["C01"], "default_aid_type":["C01"], "default_aid_type_category_code":["C01"], "default_aid_type_code":["C01"], "default-tied-status.code":"5", "default_tied_status_code":"5", "budget.status":["2","2"], "budget_status":["2","2"], "budget.type":["2","1"], "budget_type":["2","1"], "budget.period-start.iso-date":["2025-04-01T00:00:00Z","2024-04-01T00:00:00Z"], "budget_period_start_iso_date":["2025-04-01T00:00:00Z","2024-04-01T00:00:00Z"], "budget.period-end.iso-date":["2026-03-31T00:00:00Z","2025-03-31T00:00:00Z"], "budget_period_end_iso_date":["2026-03-31T00:00:00Z","2025-03-31T00:00:00Z"], "budget.value":[0.0,959000.0], "budget_value":[0.0,959000.0], "budget.value.currency":["CAD","CAD"], "budget_value_currency":["CAD","CAD"], "budget.value.value-date":["2026-03-31T00:00:00Z","2025-03-31T00:00:00Z"], "budget_value_date":["2026-03-31T00:00:00Z","2025-03-31T00:00:00Z"], "planned-disbursement.type":["1","1","1"], "planned_disbursement_type":["1","1","1"], "planned-disbursement.period-start.iso-date":["2024-04-01T00:00:00Z","2025-04-01T00:00:00Z","2027-04-01T00:00:00Z"], "planned_disbursement_period_start_iso_date":["2024-04-01T00:00:00Z","2025-04-01T00:00:00Z","2027-04-01T00:00:00Z"], "planned-disbursement.period-end.iso-date":["2025-03-31T00:00:00Z","2026-03-31T00:00:00Z","2028-03-31T00:00:00Z"], "planned_disbursement_period_end_iso_date":["2025-03-31T00:00:00Z","2026-03-31T00:00:00Z","2028-03-31T00:00:00Z"], "planned-disbursement.value":[455525.0,455525.0,47950.0], "planned_disbursement_value":[455525.0,455525.0,47950.0], "planned-disbursement.provider-org.type":["15","15","15"], "planned_disbursement_provider_org_type":["15","15","15"], "planned-disbursement.provider-org.ref":["XM-DAC-301-2","XM-DAC-301-2","XM-DAC-301-2"], "planned_disbursement_provider_org_ref":["XM-DAC-301-2","XM-DAC-301-2","XM-DAC-301-2"], "planned-disbursement.provider-org.narrative":["International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international"], "planned_disbursement_provider_org_narrative":["International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international"], "planned_disbursement_provider_org_narrative_text":["International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international"], "planned-disbursement.provider-org.narrative.lang":["en","fr","en","fr","en","fr"], "planned_disbursement_provider_org_narrative_lang":["en","fr","en","fr","en","fr"], "planned-disbursement.receiver-org.type":["80","80","80"], "planned_disbursement_receiver_org_type":["80","80","80"], "planned-disbursement.receiver-org.narrative":["The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois"], "planned_disbursement_receiver_org_narrative":["The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois"], "planned_disbursement_receiver_org_narrative_text":["The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois"], "planned-disbursement.receiver-org.narrative.lang":["en","en","en"], "planned_disbursement_receiver_org_narrative_lang":["en","en","en"], "planned-disbursement.value.currency":["CAD","CAD","CAD"], "planned_disbursement_value_currency":["CAD","CAD","CAD"], "planned-disbursement.value.value-date":["2024-04-01T00:00:00Z","2025-04-01T00:00:00Z","2027-04-01T00:00:00Z"], "planned_disbursement_value_date":["2024-04-01T00:00:00Z","2025-04-01T00:00:00Z","2027-04-01T00:00:00Z"], "transaction.transaction-type.code":["3","3","2","2","11","11"], "transaction_type":["3","3","2","2","11","11"], "transaction.transaction-date.iso-date":["2024-09-30T00:00:00Z","2025-09-30T00:00:00Z","2024-09-30T00:00:00Z","2025-09-30T00:00:00Z","2024-09-30T00:00:00Z","2024-09-30T00:00:00Z"], "transaction_date_iso_date":["2024-09-30T00:00:00Z","2025-09-30T00:00:00Z","2024-09-30T00:00:00Z","2025-09-30T00:00:00Z","2024-09-30T00:00:00Z","2024-09-30T00:00:00Z"], "transaction.value":[455525.0,455525.0,455525.0,455525.0,594362.19,364637.81], "transaction_value":[455525.0,455525.0,455525.0,455525.0,594362.19,364637.81], "transaction.description.narrative":["Disbursement","Décaissement","Disbursement","Décaissement","Outgoing Commitment","Engagement sortant","Outgoing Commitment","Engagement sortant","Incoming Commitment","Engagement entrant","Incoming Commitment","Engagement entrant"], "transaction_description_narrative":["Disbursement","Décaissement","Disbursement","Décaissement","Outgoing Commitment","Engagement sortant","Outgoing Commitment","Engagement sortant","Incoming Commitment","Engagement entrant","Incoming Commitment","Engagement entrant"], "transaction.description.narrative.lang":["en","fr","en","fr","en","fr","en","fr","en","fr","en","fr"], "transaction_description_lang":["en","fr","en","fr","en","fr","en","fr","en","fr","en","fr"], "transaction.provider-org.type":["15","15","15","15","10","15"], "transaction_provider_org_type":["15","15","15","15","10","15"], "transaction.provider-org.ref":["XM-DAC-301-2","XM-DAC-301-2","XM-DAC-301-2","XM-DAC-301-2","GB-GOV-10","XM-DAC-301-2"], "transaction_provider_org_ref":["XM-DAC-301-2","XM-DAC-301-2","XM-DAC-301-2","XM-DAC-301-2","GB-GOV-10","XM-DAC-301-2"], "transaction.provider-org.narrative":["International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international","United Kingdom. Department of Health and Social Care","Canada. Parliament","Canada. Parlement","Canadá. Parlamento"], "transaction_provider_org_narrative":["International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international","United Kingdom. Department of Health and Social Care","Canada. Parliament","Canada. Parlement","Canadá. Parlamento"], "transaction_provider_org_narrative_text":["International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international","United Kingdom. Department of Health and Social Care","Canada. Parliament","Canada. Parlement","Canadá. Parlamento"], "transaction.provider-org.narrative.lang":["en","fr","en","fr","en","fr","en","fr","en","en","fr","es"], "transaction_provider_org_narrative_lang":["en","fr","en","fr","en","fr","en","fr","en","en","fr","es"], "transaction.receiver-org.type":["80","80","80","80","15","15"], "transaction_receiver_org_type_code":["80","80","80","80","15","15"], "transaction.receiver-org.narrative":["The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois","International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international"], "transaction_receiver_org_narrative":["The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois","International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international"], "transaction_receiver_org_narrative_text":["The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois","The Board of Trustees of the University of Illinois","International Development Research Centre","Centre de recherches pour le développement international","International Development Research Centre","Centre de recherches pour le développement international"], "transaction.receiver-org.narrative.lang":["en","en","en","en","en","fr","en","fr"], "transaction_receiver_org_narrative_lang":["en","en","en","en","en","fr","en","fr"], "transaction.disbursement-channel.code":["2","2","2","2","2","2"], "transaction_disbursement_channel_code":["2","2","2","2","2","2"], "transaction.value.currency":["CAD","CAD","CAD","CAD","CAD","CAD"], "transaction_value_currency":["CAD","CAD","CAD","CAD","CAD","CAD"], "transaction.value.value-date":["2024-09-30T00:00:00Z","2025-09-30T00:00:00Z","2024-09-30T00:00:00Z","2025-09-30T00:00:00Z","2024-09-30T00:00:00Z","2024-09-30T00:00:00Z"], "transaction_value_date":["2024-09-30T00:00:00Z","2025-09-30T00:00:00Z","2024-09-30T00:00:00Z","2025-09-30T00:00:00Z","2024-09-30T00:00:00Z","2024-09-30T00:00:00Z"], "transaction.provider-org.provider-activity-id":["GB-GOV-10-GAMRIF-WP3-Inno-Vet-AMR"], "transaction_provider_org_provider_activity_id":["GB-GOV-10-GAMRIF-WP3-Inno-Vet-AMR"], "transaction.receiver-org.ref":["XM-DAC-301-2","XM-DAC-301-2"], "transaction_receiver_org_ref":["XM-DAC-301-2","XM-DAC-301-2"], "related-activity.ref":["XM-DAC-301-2-110336-002"], "related_activity_ref":["XM-DAC-301-2-110336-002"], "related-activity.type":["3"], "related_activity_type":["3"], "conditions.attached":true, "conditions_attached":"1", "conditions.condition.type":["3","2"], "conditions_condition_type":["3","2"], "conditions.condition.narrative":["Grant is conditional on periodic submission of a detailed accounting of expenditure of funds received from IDRC accompanied by estimation of budget for the next reporting period","La bourse est octroyée à condition de périodiquement présenter une justification détaillée de l'utilisation des fonds versés par le CRDI ainsi qu'une estimation budgétaire de la période de rapport suivante","Grant is conditional on completion of specified terms of reference, receipt of specified deliverables","La bourse est octroyée à condition de respecter le mandat établi et de livrer les résultats attendus"], "conditions_condition_narrative":["Grant is conditional on periodic submission of a detailed accounting of expenditure of funds received from IDRC accompanied by estimation of budget for the next reporting period","La bourse est octroyée à condition de périodiquement présenter une justification détaillée de l'utilisation des fonds versés par le CRDI ainsi qu'une estimation budgétaire de la période de rapport suivante","Grant is conditional on completion of specified terms of reference, receipt of specified deliverables","La bourse est octroyée à condition de respecter le mandat établi et de livrer les résultats attendus"], "conditions_condition_narrative_text":["Grant is conditional on periodic submission of a detailed accounting of expenditure of funds received from IDRC accompanied by estimation of budget for the next reporting period","La bourse est octroyée à condition de périodiquement présenter une justification détaillée de l'utilisation des fonds versés par le CRDI ainsi qu'une estimation budgétaire de la période de rapport suivante","Grant is conditional on completion of specified terms of reference, receipt of specified deliverables","La bourse est octroyée à condition de respecter le mandat établi et de livrer les résultats attendus"], "conditions.condition.narrative.lang":["en","fr","en","fr"], "conditions_condition_narrative_lang":["en","fr","en","fr"], "reporting-org.type.name":"Other Public Sector", "reporting_org_type_name":"Other Public Sector", "recipient-country.name":["Ethiopia"], "recipient_country_name":["Ethiopia"], "default-aid-type.name":["Project-type interventions"], "default_aid_type_category_name":["Project-type interventions"], "policy-marker.name":["Gender Equality","Aid to Environment","Participatory Development/Good Governance","Trade Development","Aid Targeting the Objectives of the Convention on Biological Diversity","Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation","Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation","Aid Targeting the Objectives of the Convention to Combat Desertification","Reproductive, Maternal, Newborn and Child Health (RMNCH)"], "policy-marker.significance.name":["not targeted","not targeted","not targeted","not targeted","not targeted","not targeted","not targeted","not targeted","not targeted"], "policy-marker.vocabulary.name":["OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS"], "budget.type.name":["Revised","Original"], "budget.status.name":["Committed","Committed"], "transaction.receiver-org.type.name":["Academic, Training and Research","Academic, Training and Research","Academic, Training and Research","Academic, Training and Research","Other Public Sector","Other Public Sector"], "transaction_receiver_org_type_name":["Academic, Training and Research","Academic, Training and Research","Academic, Training and Research","Academic, Training and Research","Other Public Sector","Other Public Sector"], "title.narrative.first":"Novel nanoparticle therapeutics as alternatives to antibiotics to control Escherichia coli bacterial infection in ruminants in Ethiopia", "title_narrative_first":"Novel nanoparticle therapeutics as alternatives to antibiotics to control Escherichia coli bacterial infection in ruminants in Ethiopia", "activity-date.start-actual":"2024-06-20T00:00:00Z", "activity_date_start_actual":"Thu Jun 20 00:00:00 UTC 2024", "activity_date_start_actual_f":"2024-06-20T00:00:00Z", "activity-date.common.start":"2024-06-20T00:00:00Z", "activity_date_start_common":"Thu Jun 20 00:00:00 UTC 2024", "activity_date_start_common_f":"2024-06-20T00:00:00Z", "activity-date.end-planned":"2027-01-20T00:00:00Z", "activity_date_end_planned":"Wed Jan 20 00:00:00 UTC 2027", "activity_date_end_planned_f":"2027-01-20T00:00:00Z", "activity-date.common.end":"2027-01-20T00:00:00Z", "activity_date_end_common":"Wed Jan 20 00:00:00 UTC 2027", "activity_date_end_common_f":"2027-01-20T00:00:00Z", "activity-status.text":"Implementation", "activity_status_text":"Implementation", "policy-marker.combined":["1__0","2__0","3__0","4__0","5__0","6__0","7__0","8__0","9__0"], "policy_marker_combined":["1__0","2__0","3__0","4__0","5__0","6__0","7__0","8__0","9__0"], "budget.value-usd":[664679.6045740624], "budget_value_usd":[664679.6045740624], "budget.value-usd.sum":664679.6045740624, "budget_value_usd_sum":664679.6045740624, "budget.value-usd.conversion-rate":[1.4428004009759603], "budget_usd_conversion_rate":[1.4428004009759603], "budget.value-usd.conversion-currency":["CAD"], "budget.value-gbp":[525002.68179239], "budget_value_gbp":[525002.68179239], "budget.value-gbp.sum":525002.68179239, "budget_value_gbp_sum":525002.68179239, "budget.value-gbp.conversion-rate":[1.8266573357795388], "budget_gbp_conversion_rate":[1.8266573357795388], "budget.value-gbp.conversion-currency":["CAD"], "planned-disbursement.value-usd":[34653.49124911341], "planned_disbursement_value_usd":[34653.49124911341], "planned-disbursement.value-usd.sum":34653.49124911341, "planned_disbursement_value_usd_sum":34653.49124911341, "planned-disbursement.value-usd.conversion-rate":[1.3836989657204244], "planned_disbursement_usd_conversion_rate":[1.3836989657204244], "planned-disbursement.value-usd.conversion-currency":["CAD"], "planned-disbursement.value-gbp":[25739.796112436667], "planned_disbursement_value_gbp":[25739.796112436667], "planned-disbursement.value-gbp.sum":25739.796112436667, "planned_disbursement_value_gbp_sum":25739.796112436667, "planned-disbursement.value-gbp.conversion-rate":[1.862874118759319], "planned_disbursement_gbp_conversion_rate":[1.862874118759319], "planned-disbursement.value-gbp.conversion-currency":["CAD"], "transaction.value-usd.sum":660707.6599913969, "transaction_value_usd_sum":660707.6599913969, "transaction.value-usd.conversion-rate":[1.3789003142658627,1.3789003142658627], "transaction_usd_conversion_rate":[1.3789003142658627,1.3789003142658627], "transaction.value-usd.conversion-currency":["CAD"], "transaction.value-gbp.sum":493950.1893763443, "transaction_value_gbp_sum":493950.1893763443, "transaction.value-gbp.conversion-rate":[1.8444167440249004,1.8444167440249004], "transaction_gbp_conversion_rate":[1.8444167440249004,1.8444167440249004], "transaction.value-gbp.conversion-currency":["CAD"], "dataset.id":"a2a61343-2f15-490c-86a4-37d26da68931", "dataset_iati_id":"a2a61343-2f15-490c-86a4-37d26da68931", "dataset.name":"idrccrdi-act-active", "dataset_name":"idrccrdi-act-active", "dataset.extras.iati_version":"2.03", "dataset.resources.hash":"b7aa385e30c35aef471ba874cdf83e2bc6f033a2", "dataset.resources.url":"https://idrc-crdi.ca/sites/default/files/2026-03/idrc_iati_activities_Active_2025-04-01_2025-12-31.xml", "hierarchy":1, "activity-date.quarter":[2,1], "budget.period-start.quarter":[2,2], "budget.period-end.quarter":[1,1], "planned-disbursement.period-start.quarter":[2,2,2], "planned-disbursement.period-end.quarter":[1,1,1], "transaction.transaction-date.quarter":[3,3,3,3,3,3], "transaction.value-usd":[330353.82999569847,330353.82999569847], "transaction_value_usd":[330353.82999569847,330353.82999569847], "transaction.value-usd-type":[3,3,2,2,11,11], "transaction.value-gbp":[246975.09468817216,246975.09468817216], "transaction_value_gbp":[246975.09468817216,246975.09468817216], "transaction.value-gbp-type":[3,3,2,2,11,11], "activity-aggregation.budget.value":959000.0, "activity_aggregation_budget_value":959000.0, "activity-aggregation.budget.value-usd":664679.6045740624, "activity_aggregation_budget_value_usd":664679.6045740624, "activity-aggregation.budget.value-gbp":525002.68179239, "activity_aggregation_budget_value_gbp":525002.68179239, "activity-aggregation.budget.currency":"CAD", "activity_aggregation_budget_currency":"CAD", "activity-aggregation.planned-disbursement.value":959000.0, "activity-aggregation.planned-disbursement.value-usd":34653.49124911341, "activity-aggregation.planned-disbursement.value-gbp":25739.796112436667, "activity-aggregation.planned-disbursement.currency":"CAD", "activity-aggregation.outgoing-commitment.value":911050.0, "activity_aggregation_commitment_value":911050.0, "activity-aggregation.outgoing-commitment.value-usd":330353.82999569847, "activity_aggregation_commitment_value_usd":330353.82999569847, "activity-aggregation.outgoing-commitment.value-gbp":246975.09468817216, "activity_aggregation_commitment_value_gbp":246975.09468817216, "activity-aggregation.disbursement.value":911050.0, "activity_aggregation_disbursement_value":911050.0, "activity-aggregation.disbursement.value-usd":330353.82999569847, "activity_aggregation_disbursement_value_usd":330353.82999569847, "activity-aggregation.disbursement.value-gbp":246975.09468817216, "activity_aggregation_disbursement_value_gbp":246975.09468817216, "activity-aggregation.incoming-commitment.value":959000.0, "activity_aggregation_incoming_commitment_value":959000.0, "activity-aggregation.incoming-commitment.value-usd":0.0, "activity_aggregation_incoming_commitment_value_usd":0.0, "activity-aggregation.incoming-commitment.value-gbp":0.0, "activity_aggregation_incoming_commitment_value_gbp":0.0, "json.reporting-org":"{\"type\": 15, \"ref\": \"XM-DAC-301-2\", \"narrative\": [\"International Development Research Centre\", \"Centre de recherches pour le d\\u00e9veloppement international\", \"Centro Internacional de Investigaciones para el Desarrollo\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\", \"es\"]}", "json.title":"{\"narrative\": [\"Novel nanoparticle therapeutics as alternatives to antibiotics to control Escherichia coli bacterial infection in ruminants in Ethiopia\", \"Nouvelles nanoparticules th\\u00e9rapeutiques comme alternatives aux antibiotiques pour contr\\u00f4ler l\\u2019infection bact\\u00e9rienne \\u00e0 E coli chez les ruminants en \\u00c9th\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}", "json.description":["{\"type\": 1, \"narrative\": [\"The dairy productivity of Ethiopian cattle is largely affected by neonatal mortality caused by infectious diseases. Bovine colibacillosis caused by enterotoxigenic Escherichia coli (E coli) is mainly responsible for diarrhea in calves. Currently, antimicrobials are the main line of treatment for bovine colibacillosis. The emergence of multidrug-resistant E coli strains, responsible for high mortality and morbidity, demonstrates an urgent need for the development of alternative antimicrobials. \\n\\nThe central hypothesis of this research project is that small molecule inhibitors and antimicrobial peptides targeting the outer membrane proteins of E coli can be developed into safe and effective therapies for multidrug-resistant infections. The main objective is to develop an innovative delivery system and evaluate its efficacy, safety and applicability against bovine colibacillosis.\\u202fThe study outcomes can lead to a more effective means for managing calf diarrhea in Ethiopia, which will promote sustainable animal agriculture, improve food security and reduce reliance on antibiotics. These findings will have broader implications for mitigating antimicrobial resistance in other low- and middle-income countries.\\u202f \\n\\nThis project is part of the InnoVet-AMR 2.0 program, a four-year partnership between IDRC and the United Kingdom\\u2019s Department of Health and Social Care. The initiative is aimed at reducing the emerging risk that antimicrobial resistance in animals poses to global health and food security.\", \"La productivit\\u00e9 laiti\\u00e8re du b\\u00e9tail \\u00e9thiopien est largement touch\\u00e9e par la mortalit\\u00e9 n\\u00e9onatale caus\\u00e9e par les maladies infectieuses. La colibacillose bovine caus\\u00e9e par Escherichia coli ent\\u00e9rotoxique (E coli) est principalement responsable de la diarrh\\u00e9e chez les veaux. Actuellement, les antimicrobiens constituent la principale ligne de traitement de la colibacillose bovine. L\\u2019\\u00e9mergence de souches d\\u2019E. coli multir\\u00e9sistantes, responsables d\\u2019une mortalit\\u00e9 et d\\u2019une morbidit\\u00e9 \\u00e9lev\\u00e9es, montre qu\\u2019il est urgent de d\\u00e9velopper des antimicrobiens alternatifs. \\n\\nL\\u2019hypoth\\u00e8se centrale de ce projet de recherche est que les petites mol\\u00e9cules inhibitrices et les peptides antimicrobiens ciblant les prot\\u00e9ines de la membrane externe d\\u2019E. coli peuvent \\u00eatre d\\u00e9velopp\\u00e9s en th\\u00e9rapies s\\u00fbres et efficaces pour les infections multir\\u00e9sistantes. L\\u2019objectif principal est de d\\u00e9velopper un syst\\u00e8me d\\u2019administration innovant et d\\u2019\\u00e9valuer son efficacit\\u00e9, sa s\\u00e9curit\\u00e9 et son applicabilit\\u00e9 contre la colibacillose bovine.\\u202fLes r\\u00e9sultats de l\\u2019\\u00e9tude peuvent d\\u00e9boucher sur un moyen plus efficace de g\\u00e9rer la diarrh\\u00e9e du veau en \\u00c9thiopie, ce qui favorisera une agriculture animale durable, am\\u00e9liorera la s\\u00e9curit\\u00e9 alimentaire et r\\u00e9duira la d\\u00e9pendance \\u00e0 l\\u2019\\u00e9gard des antibiotiques. Ces r\\u00e9sultats auront des r\\u00e9percussions plus larges pour att\\u00e9nuer la r\\u00e9sistance aux antimicrobiens dans d\\u2019autres pays \\u00e0 revenu faible ou interm\\u00e9diaire.\\u202f \\n\\nCe projet fait partie du programme Solutions v\\u00e9t\\u00e9rinaires innovatrices pour la r\\u00e9sistance aux antimicrobiens 2.0 (InnoVet-AMR 2.0), un partenariat de quatre ans entre le CRDI et le Department of Health and Social Care du Royaume-Uni. L\\u2019initiative vise \\u00e0 r\\u00e9duire les risques \\u00e9mergents que pose la r\\u00e9sistance aux antimicrobiens chez les animaux pour la sant\\u00e9 mondiale et la s\\u00e9curit\\u00e9 alimentaire.\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}"], "json.participating-org":["{\"role\": 4, \"type\": 80, \"narrative\": \"The Board of Trustees of the University of Illinois\", \"narrative.lang\": \"en\"}","{\"role\": 1, \"type\": 10, \"ref\": \"GB-GOV-10\", \"activity-id\": \"GB-GOV-10-GAMRIF-WP3-Inno-Vet-AMR\", \"narrative\": \"United Kingdom. Department of Health and Social Care\", \"narrative.lang\": \"en\"}","{\"role\": 1, \"type\": 10, \"ref\": \"XM-DAC-301-2\", \"narrative\": [\"Canada. Parliament\", \"Canada. Parlement\", \"Canad\\u00e1. Parlamento\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\", \"es\"]}","{\"role\": 2, \"type\": 80, \"narrative\": \"The Board of Trustees of the University of Illinois\", \"narrative.lang\": \"en\"}","{\"role\": 3, \"type\": 15, \"ref\": \"XM-DAC-301-2\", \"narrative\": [\"International Development Research Centre\", \"Centre de recherches pour le d\\u00e9veloppement international\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}"], "json.activity-date":["{\"iso-date\": \"2024-06-20\", \"type\": 2}","{\"iso-date\": \"2027-01-20\", \"type\": 3}"], "json.contact-info":["{\"type\": 1, \"organisation\": {\"narrative\": [\"International Development Research Centre\", \"Centre de recherches pour le d\\u00e9veloppement international\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"telephone\": \"(+1) 613-236-6163\", \"email\": \"info@idrc.ca\", \"website\": \"http://www.idrc.ca\", \"mailing-address\": {\"narrative\": [\"PO Box 8500, Ottawa ON Canada, K1G 3H9\", \"CP 8500, Ottawa ON Canada, K1G 3H9\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}}"], "json.recipient-country":["{\"code\": \"ET\", \"percentage\": 100}"], "json.sector":["{\"vocabulary\": 1, \"code\": 31182, \"percentage\": 100}"], "json.policy-marker":["{\"vocabulary\": 1, \"code\": 1, \"significance\": 0}","{\"vocabulary\": 1, \"code\": 2, \"significance\": 0}","{\"vocabulary\": 1, \"code\": 3, \"significance\": 0}","{\"vocabulary\": 1, \"code\": 4, \"significance\": 0}","{\"vocabulary\": 1, \"code\": 5, \"significance\": 0}","{\"vocabulary\": 1, \"code\": 6, \"significance\": 0}","{\"vocabulary\": 1, \"code\": 7, \"significance\": 0}","{\"vocabulary\": 1, \"code\": 8, \"significance\": 0}","{\"vocabulary\": 1, \"code\": 9, \"significance\": 0}"], "json.default-aid-type":["{\"code\": \"C01\"}"], "json.budget":["{\"status\": 2, \"type\": 2, \"period-start\": [{\"iso-date\": \"2025-04-01\"}], \"period-end\": [{\"iso-date\": \"2026-03-31\"}], \"value\": 0.0, \"value.currency\": \"CAD\", \"value.value-date\": \"2026-03-31\"}","{\"status\": 2, \"type\": 1, \"period-start\": [{\"iso-date\": \"2024-04-01\"}], \"period-end\": [{\"iso-date\": \"2025-03-31\"}], \"value\": 959000.0, \"value.currency\": \"CAD\", \"value.value-date\": \"2025-03-31\"}"], "json.planned-disbursement":["{\"type\": 1, \"period-start\": [{\"iso-date\": \"2024-04-01\"}], \"period-end\": [{\"iso-date\": \"2025-03-31\"}], \"value\": 455525.0, \"provider-org\": {\"type\": 15, \"ref\": \"XM-DAC-301-2\", \"narrative\": [\"International Development Research Centre\", \"Centre de recherches pour le d\\u00e9veloppement international\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"receiver-org\": {\"type\": 80, \"narrative\": \"The Board of Trustees of the University of Illinois\", \"narrative.lang\": \"en\"}, \"value.currency\": \"CAD\", \"value.value-date\": \"2024-04-01\"}","{\"type\": 1, \"period-start\": [{\"iso-date\": \"2025-04-01\"}], \"period-end\": [{\"iso-date\": \"2026-03-31\"}], \"value\": 455525.0, \"provider-org\": {\"type\": 15, \"ref\": \"XM-DAC-301-2\", \"narrative\": [\"International Development Research Centre\", \"Centre de recherches pour le d\\u00e9veloppement international\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"receiver-org\": {\"type\": 80, \"narrative\": \"The Board of Trustees of the University of Illinois\", \"narrative.lang\": \"en\"}, \"value.currency\": \"CAD\", \"value.value-date\": \"2025-04-01\"}","{\"type\": 1, \"period-start\": [{\"iso-date\": \"2027-04-01\"}], \"period-end\": [{\"iso-date\": \"2028-03-31\"}], \"value\": 47950.0, \"provider-org\": {\"type\": 15, \"ref\": \"XM-DAC-301-2\", \"narrative\": [\"International Development Research Centre\", \"Centre de recherches pour le d\\u00e9veloppement international\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"receiver-org\": {\"type\": 80, \"narrative\": \"The Board of Trustees of the University of Illinois\", \"narrative.lang\": \"en\"}, \"value.currency\": \"CAD\", \"value.value-date\": \"2027-04-01\"}"], "json.transaction":["{\"transaction-type\": {\"code\": 3}, \"transaction-date\": {\"iso-date\": \"2024-09-30\"}, \"value\": 455525.0, \"description\": {\"narrative\": [\"Disbursement\", \"D\\u00e9caissement\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"provider-org\": {\"type\": 15, \"ref\": \"XM-DAC-301-2\", \"narrative\": [\"International Development Research Centre\", \"Centre de recherches pour le d\\u00e9veloppement international\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"receiver-org\": {\"type\": 80, \"narrative\": \"The Board of Trustees of the University of Illinois\", \"narrative.lang\": \"en\"}, \"disbursement-channel\": {\"code\": 2}, \"value.currency\": \"CAD\", \"value.value-date\": \"2024-09-30\"}","{\"transaction-type\": {\"code\": 3}, \"transaction-date\": {\"iso-date\": \"2025-09-30\"}, \"value\": 455525.0, \"description\": {\"narrative\": [\"Disbursement\", \"D\\u00e9caissement\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"provider-org\": {\"type\": 15, \"ref\": \"XM-DAC-301-2\", \"narrative\": [\"International Development Research Centre\", \"Centre de recherches pour le d\\u00e9veloppement international\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"receiver-org\": {\"type\": 80, \"narrative\": \"The Board of Trustees of the University of Illinois\", \"narrative.lang\": \"en\"}, \"disbursement-channel\": {\"code\": 2}, \"value.currency\": \"CAD\", \"value.value-date\": \"2025-09-30\"}","{\"transaction-type\": {\"code\": 2}, \"transaction-date\": {\"iso-date\": \"2024-09-30\"}, \"value\": 455525.0, \"description\": {\"narrative\": [\"Outgoing Commitment\", \"Engagement sortant\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"provider-org\": {\"type\": 15, \"ref\": \"XM-DAC-301-2\", \"narrative\": [\"International Development Research Centre\", \"Centre de recherches pour le d\\u00e9veloppement international\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"receiver-org\": {\"type\": 80, \"narrative\": \"The Board of Trustees of the University of Illinois\", \"narrative.lang\": \"en\"}, \"disbursement-channel\": {\"code\": 2}, \"value.currency\": \"CAD\", \"value.value-date\": \"2024-09-30\"}","{\"transaction-type\": {\"code\": 2}, \"transaction-date\": {\"iso-date\": \"2025-09-30\"}, \"value\": 455525.0, \"description\": {\"narrative\": [\"Outgoing Commitment\", \"Engagement sortant\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"provider-org\": {\"type\": 15, \"ref\": \"XM-DAC-301-2\", \"narrative\": [\"International Development Research Centre\", \"Centre de recherches pour le d\\u00e9veloppement international\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"receiver-org\": {\"type\": 80, \"narrative\": \"The Board of Trustees of the University of Illinois\", \"narrative.lang\": \"en\"}, \"disbursement-channel\": {\"code\": 2}, \"value.currency\": \"CAD\", \"value.value-date\": \"2025-09-30\"}","{\"transaction-type\": {\"code\": 11}, \"transaction-date\": {\"iso-date\": \"2024-09-30\"}, \"value\": 594362.19, \"description\": {\"narrative\": [\"Incoming Commitment\", \"Engagement entrant\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"provider-org\": {\"type\": 10, \"provider-activity-id\": \"GB-GOV-10-GAMRIF-WP3-Inno-Vet-AMR\", \"ref\": \"GB-GOV-10\", \"narrative\": \"United Kingdom. Department of Health and Social Care\", \"narrative.lang\": \"en\"}, \"receiver-org\": {\"type\": 15, \"ref\": \"XM-DAC-301-2\", \"narrative\": [\"International Development Research Centre\", \"Centre de recherches pour le d\\u00e9veloppement international\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"disbursement-channel\": {\"code\": 2}, \"value.currency\": \"CAD\", \"value.value-date\": \"2024-09-30\"}","{\"transaction-type\": {\"code\": 11}, \"transaction-date\": {\"iso-date\": \"2024-09-30\"}, \"value\": 364637.81, \"description\": {\"narrative\": [\"Incoming Commitment\", \"Engagement entrant\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"provider-org\": {\"type\": 15, \"ref\": \"XM-DAC-301-2\", \"narrative\": [\"Canada. Parliament\", \"Canada. Parlement\", \"Canad\\u00e1. Parlamento\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\", \"es\"]}, \"receiver-org\": {\"type\": 15, \"ref\": \"XM-DAC-301-2\", \"narrative\": [\"International Development Research Centre\", \"Centre de recherches pour le d\\u00e9veloppement international\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, \"disbursement-channel\": {\"code\": 2}, \"value.currency\": \"CAD\", \"value.value-date\": \"2024-09-30\"}"], "json.related-activity":["{\"ref\": \"XM-DAC-301-2-110336-002\", \"type\": 3}"], "json.conditions":"{\"attached\": 1, \"condition\": [{\"type\": 3, \"narrative\": [\"Grant is conditional on periodic submission of a detailed accounting of expenditure of funds received from IDRC accompanied by estimation of budget for the next reporting period\", \"La bourse est octroy\\u00e9e \\u00e0 condition de p\\u00e9riodiquement pr\\u00e9senter une justification d\\u00e9taill\\u00e9e de l'utilisation des fonds vers\\u00e9s par le CRDI ainsi qu'une estimation budg\\u00e9taire de la p\\u00e9riode de rapport suivante\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}, {\"type\": 2, \"narrative\": [\"Grant is conditional on completion of specified terms of reference, receipt of specified deliverables\", \"La bourse est octroy\\u00e9e \\u00e0 condition de respecter le mandat \\u00e9tabli et de livrer les r\\u00e9sultats attendus\"], \"narrative.currency\": [], \"narrative.value_date\": [], \"narrative.year\": [], \"narrative.lang\": [\"en\", \"fr\"]}]}", "related_budget_value":[0,641000], "related_budget_period_start_quarter":[2,2], "related_budget_period_end_quarter":[1,1], "related_budget_period_start_iso_date":["2025-04-01T00:00:00Z","2024-04-01T00:00:00Z"], "related_budget_period_end_iso_date":["2026-03-31T00:00:00Z","2025-03-31T00:00:00Z"], "id":"779ac3a5-ba7b-4d19-987a-b2ccd944b769", "related_activity_context":"ID: XM-DAC-301-2-110336-001\nTitle: Novel nanoparticle therapeutics as alternatives to antibiotics to control Escherichia coli bacterial infection in ruminants in Ethiopia. Nouvelles nanoparticules thérapeutiques comme alternatives aux antibiotiques pour contrôler l’infection bactérienne à E coli chez les ruminants en Éth\nDescription: The dairy productivity of Ethiopian cattle is largely affected by neonatal mortality caused by infectious diseases. Bovine colibacillosis caused by enterotoxigenic Escherichia coli (E coli) is mainly responsible for diarrhea in calves. Currently, antimicrobials are the main line of treatment for bovine colibacillosis. The emergence of multidrug-resistant E coli strains, responsible for high mortality and morbidity, demonstrates an urgent need for the development of alternative antimicrobials. \n\nThe central hypothesis of this research project is that small molecule inhibitors and antimicrobial peptides targeting the outer membrane proteins of E coli can be developed into safe and effective therapies for multidrug-resistant infections. The main objective is to develop an innovative delivery system and evaluate its efficacy, safety and applicability against bovine colibacillosis. The study outcomes can lead to a more effective means for managing calf diarrhea in Ethiopia, which will promote sustainable animal agriculture, improve food security and reduce reliance on antibiotics. These findings will have broader implications for mitigating antimicrobial resistance in other low- and middle-income countries.  \n\nThis project is part of the InnoVet-AMR 2.0 program, a four-year partnership between IDRC and the United Kingdom’s Department of Health and Social Care. The initiative is aimed at reducing the emerging risk that antimicrobial resistance in animals poses to global health and food security.. La productivité laitière du bétail éthiopien est largement touchée par la mortalité néonatale causée par les maladies infectieuses. La colibacillose bovine causée par Escherichia coli entérotoxique (E coli) est principalement responsable de la diarrhée chez les veaux. Actuellement, les antimicrobiens constituent la principale ligne de traitement de la colibacillose bovine. L’émergence de souches d’E. coli multirésistantes, responsables d’une mortalité et d’une morbidité élevées, montre qu’il est urgent de développer des antimicrobiens alternatifs. \n\nL’hypothèse centrale de ce projet de recherche est que les petites molécules inhibitrices et les peptides antimicrobiens ciblant les protéines de la membrane externe d’E. coli peuvent être développés en thérapies sûres et efficaces pour les infections multirésistantes. L’objectif principal est de développer un système d’administration innovant et d’évaluer son efficacité, sa sécurité et son applicabilité contre la colibacillose bovine. Les résultats de l’étude peuvent déboucher sur un moyen plus efficace de gérer la diarrhée du veau en Éthiopie, ce qui favorisera une agriculture animale durable, améliorera la sécurité alimentaire et réduira la dépendance à l’égard des antibiotiques. Ces résultats auront des répercussions plus larges pour atténuer la résistance aux antimicrobiens dans d’autres pays à revenu faible ou intermédiaire.  \n\nCe projet fait partie du programme Solutions vétérinaires innovatrices pour la résistance aux antimicrobiens 2.0 (InnoVet-AMR 2.0), un partenariat de quatre ans entre le CRDI et le Department of Health and Social Care du Royaume-Uni. L’initiative vise à réduire les risques émergents que pose la résistance aux antimicrobiens chez les animaux pour la santé mondiale et la sécurité alimentaire.\n \n ID: XM-DAC-301-2-110336-002\nTitle: Novel nanoparticle therapeutics as alternatives to antibiotics to control Escherichia coli bacterial infection in ruminants in Ethiopia. Nouvelles nanoparticules thérapeutiques comme alternatives aux antibiotiques pour contrôler l’infection bactérienne à E coli chez les ruminants en Éth\nDescription: The dairy productivity of Ethiopian cattle is largely affected by neonatal mortality caused by infectious diseases. Bovine colibacillosis caused by enterotoxigenic Escherichia coli (E coli) is mainly responsible for diarrhea in calves. Currently, antimicrobials are the main line of treatment for bovine colibacillosis. The emergence of multidrug-resistant E coli strains, responsible for high mortality and morbidity, demonstrates an urgent need for the development of alternative antimicrobials. \n\nThe central hypothesis of this research project is that small molecule inhibitors and antimicrobial peptides targeting the outer membrane proteins of E coli can be developed into safe and effective therapies for multidrug-resistant infections. The main objective is to develop an innovative delivery system and evaluate its efficacy, safety and applicability against bovine colibacillosis. The study outcomes can lead to a more effective means for managing calf diarrhea in Ethiopia, which will promote sustainable animal agriculture, improve food security and reduce reliance on antibiotics. These findings will have broader implications for mitigating antimicrobial resistance in other low- and middle-income countries.  \n\nThis project is part of the InnoVet-AMR 2.0 program, a four-year partnership between IDRC and the United Kingdom’s Department of Health and Social Care. The initiative is aimed at reducing the emerging risk that antimicrobial resistance in animals poses to global health and food security.. La productivité laitière du bétail éthiopien est largement touchée par la mortalité néonatale causée par les maladies infectieuses. La colibacillose bovine causée par Escherichia coli entérotoxique (E coli) est principalement responsable de la diarrhée chez les veaux. Actuellement, les antimicrobiens constituent la principale ligne de traitement de la colibacillose bovine. L’émergence de souches d’E. coli multirésistantes, responsables d’une mortalité et d’une morbidité élevées, montre qu’il est urgent de développer des antimicrobiens alternatifs. \n\nL’hypothèse centrale de ce projet de recherche est que les petites molécules inhibitrices et les peptides antimicrobiens ciblant les protéines de la membrane externe d’E. coli peuvent être développés en thérapies sûres et efficaces pour les infections multirésistantes. L’objectif principal est de développer un système d’administration innovant et d’évaluer son efficacité, sa sécurité et son applicabilité contre la colibacillose bovine. Les résultats de l’étude peuvent déboucher sur un moyen plus efficace de gérer la diarrhée du veau en Éthiopie, ce qui favorisera une agriculture animale durable, améliorera la sécurité alimentaire et réduira la dépendance à l’égard des antibiotiques. Ces résultats auront des répercussions plus larges pour atténuer la résistance aux antimicrobiens dans d’autres pays à revenu faible ou intermédiaire.  \n\nCe projet fait partie du programme Solutions vétérinaires innovatrices pour la résistance aux antimicrobiens 2.0 (InnoVet-AMR 2.0), un partenariat de quatre ans entre le CRDI et le Department of Health and Social Care du Royaume-Uni. L’initiative vise à réduire les risques émergents que pose la résistance aux antimicrobiens chez les animaux pour la santé mondiale et la sécurité alimentaire.\n", "_version_":1868565606584811520 }] } }